Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Chembio Diagnostics (CEMI)

Chembio Diagnostics (CEMI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 84,306
  • Shares Outstanding, K 20,169
  • Annual Sales, $ 34,460 K
  • Annual Income, $ -13,680 K
  • 60-Month Beta 2.26
  • Price/Sales 1.92
  • Price/Cash Flow N/A
  • Price/Book 4.05

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.33
  • Number of Estimates 2
  • High Estimate -0.25
  • Low Estimate -0.40
  • Prior Year -0.19
  • Growth Rate Est. (year over year) -73.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.01 +33.89%
on 06/29/20
10.78 -62.63%
on 06/16/20
-4.17 (-50.85%)
since 06/05/20
3-Month
3.01 +33.89%
on 06/29/20
15.89 -74.64%
on 04/23/20
-2.18 (-35.10%)
since 04/06/20
52-Week
2.25 +79.11%
on 03/16/20
15.89 -74.64%
on 04/23/20
-1.75 (-30.28%)
since 07/05/19

Most Recent Stories

More News
Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for Chembio Diagnostics, Inc. Investors

The law firm of Kessler Topaz Meltzer & Check, LLP reminds Chembio Diagnostics, Inc. (NASDAQ: CEMI) ("Chembio") investors that a securities fraud class action lawsuit has been filed in the United States...

CEMI : 4.03 (-3.59%)
Chembio Diagnostics Announces Preliminary Estimates of Second Quarter 2020 Revenues

Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading global point-of-care diagnostic company focused on infectious diseases, today announced its preliminary estimates of revenue results for the quarter...

CEMI : 4.03 (-3.59%)
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of PRA, CEMI and CSPR

NEW YORK, NY / ACCESSWIRE / July 6, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly-traded companies. Shareholders...

PRA : 14.07 (+0.57%)
CEMI : 4.03 (-3.59%)
CSPR : 8.82 (+0.46%)
Chembio Announces Plans to Seek EUA Approval from FDA for Revised DPP COVID-19 IgM/IgG System and New DPP COVID-19 Antigen System

Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading global point-of-care diagnostic company focused on infectious diseases, today announced its plans to submit applications to the U.S. Food and Drug Administration...

CEMI : 4.03 (-3.59%)
Chembio Diagnostics Awarded BARDA Contract for Development of DPP COVID-19 Point-of-Care Antigen System

Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced it has been awarded a contract from the Biomedical Advanced Research...

CEMI : 4.03 (-3.59%)
LAWSUITS FILED AGAINST ENDP, CEMI and KL - JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS

NEW YORK, NY / ACCESSWIRE / July 6, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased...

ENDP : 3.62 (+3.58%)
CEMI : 4.03 (-3.59%)
KL : 41.93 (+0.60%)
DEADLINE ALERT for CEMI, CSPR, ENDP, USO: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed...

CEMI : 4.03 (-3.59%)
CSPR : 8.82 (+0.46%)
ENDP : 3.62 (+3.58%)
USO : 28.96 (+0.73%)
LAWSUITS FILED AGAINST PRA, CCL and CEMI - JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS

NEW YORK, NY / ACCESSWIRE / July 6, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased...

PRA : 14.07 (+0.57%)
CCL : 15.61 (-1.70%)
CEMI : 4.03 (-3.59%)
ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Reminds Chembio Diagnostics, Inc. Investors of Important August 17 Deadline in Securities Class Action - CEMI

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Chembio Diagnostics, Inc. (NASDAQ: CEMI) between March 12, 2020 and June 16, 2020, inclusive (the "Class Period")...

CEMI : 4.03 (-3.59%)
Chembio Investors: Class Action Lawsuit Filed To Recover Investment Losses

The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Chembio Diagnostic System, Inc. ("Chembio" or the "Company") investors that acquired Chembio securities (NASDAQ:...

CEMI : 4.03 (-3.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade CEMI with:

Business Summary

CHEMBIO DIAGNOSTICS, INC. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $5 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by a third party company. Chembio markets its HIV STAT-PAK...

See More

Key Turning Points

2nd Resistance Point 4.76
1st Resistance Point 4.40
Last Price 4.03
1st Support Level 3.66
2nd Support Level 3.28

See More

52-Week High 15.89
Fibonacci 61.8% 10.68
Fibonacci 50% 9.07
Fibonacci 38.2% 7.46
Last Price 4.03
52-Week Low 2.25

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar